The global mRNA therapeutics and mRNA vaccine market is witnessing steady growth, estimated to be worth USD 51.3 billion in 2023.

In recent years, the mRNA vaccine and therapeutics market has grown significantly, driven by increasing demand for targeted therapies to treat diseases that are difficult to address with conventional drugs. Messenger RNA (mRNA), a single-stranded ribonucleic acid that encodes proteins, has emerged as a revolutionary drug class for managing infectious, chronic, and oncological disorders. Pharmaceutical companies have recognized the potential of mRNA-based therapies, particularly for treating conditions such as COVID-19, genetic disorders, cancer, and other infectious diseases.

Despite its promise, the market faces challenges. Stringent regulatory guidelines and the availability of pre-existing vaccines based on other technologies have contributed to a decline in market momentum. Additionally, as the COVID-19 pandemic transitions into an endemic phase, the demand for mRNA vaccines is expected to decrease, contributing to a potential downturn in the market during the forecast period.

Competitive Landscape of the mRNA Therapeutics and Vaccine Market

Currently, the mRNA therapeutics and vaccine market landscape features more than 35 companies engaged in evaluating over 195 mRNA therapeutics and mRNA vaccines across different clinical and development stages. In the coming years, several pharmaceutical companies such as Moderna, Merck, Sanofi, and Daiichi Sankyo will enroll in strategic partnerships with mRNA-based therapeutics and vaccine developers to expand their therapy development capabilities.

Key Report Takeaway

• The pipeline features several drugs, which are being investigated across different phases of development; over 75% of the pipeline candidates are designed for delivery via the intramuscular and intravenous routes.
• The market's evolution is likely to be driven by the rising need for novel drug candidates; we expect the future opportunity to be well-distributed across various routes of administration, therapeutic areas, and key regions.
• Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds in the past nine years.
• More than 345,000 patients have been recruited / enrolled in clinical trials registered for this novel class of therapies across different geographies.
• Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipelines and comply with the evolving industry benchmarks.
• The growing interest is evident from the rise in partnership activity since 2021; clinical trial agreements have emerged as the most common type of partnership model adopted by drug developers.
• With over 195 candidates under development, mRNA therapeutics, and vaccines currently represent one of the fastest-growing drug classes in the pharmaceutical market.
• Big pharma players have undertaken several initiatives, from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market.

mRNA Therapeutics and Vaccine Market Segments

Based on the research report, Roots Analysis has segmented the mRNA Therapeutics and Vaccine market into the types of secondary packaging, primary packaging, and key geographical regions.

• mRNA Therapeutics and Vaccine Market, Based on Expertise

• mRNA Therapeutics
• mRNA Vaccines

• mRNA Therapeutics and Vaccine Market, Based on Route of Administration

• Intravenous
• Intramuscular
• Intranasal
• Others

• mRNA Therapeutics and Vaccine Market, Based on Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America
• Rest of the World

mRNA Therapeutics and Vaccine Market Geographical Outlook

The mRNA therapeutics and vaccine market based on geographical region is segmented into North America, Europe, Asia-Pacific, Latin America, the Middle East, North Africa, and the rest of the world. North America is dominating the mRNA therapeutic and vaccine market, holding the largest share of overall revenue. The National Institutes of Health supports research and development of mRNA therapeutics through grants even before the pandemic. Active support from regulatory authorities and government initiatives is driving the market in North America during the forecast period.

mRNA Therapeutics and Vaccine Market Key Players

Examples of the key companies engaged in the mRNA Therapeutics and Vaccine market (which have also been profiled in the market report; the complete list of the companies is also included in the full report) include:

• IMMORNA
• BioNTec
• eTheRNA
• Stemirna Therapeutics.
• Moderna
• Omega Therapeutics
• Chimeron Bio
• CureVac
• RNACure

It is worth noting the ongoing developments and collaborations in the mRNA therapeutics and vaccine market, which anticipate steady growth. An example of such a partnership includes:

• In August, Moderma and CARsgen Therapeutics entered into a collaboration to combine their respective mRNA therapeutics cancer vaccine with a solid tumor CAR-T cell therapy for the treatment of individuals with multiple cancers.
• In June 2023, Providence Therapeutics collaborated with the University Health Network (UHN) to develop mRNA-based therapeutics and vaccines to treat patients with cancer and infectious diseases.

In April 2023, Moderna and IBM collaborated to explore advanced next generation technologies such as artificial intelligence and quantum computing in order to enhance their mRNA research and science.

To get market data, market insights, financial statements, and a comprehensive analysis of the mRNA Therapeutics and mRNA Vaccine market, please contact sales@rootsanalysis.com

You Can Order the Complete Report on the MRNA Therapeutics and Vaccine Market Online by Clicking On the Given Link

https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

Website: https://www.rootsanalysis.com